All News
HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy?
⭐️Mean C3 ⬆️28% compared to 1st trimester
⭐️Mean C4 ⬆️ 11% compared to 1st trimester
@RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
Eric Dein ejdein1 ( View Tweet)
Looking for RA specific coverage? We've got you covered. #EULAR2021
https://t.co/eXD5UK2RRp https://t.co/RI3aMW2E2g
Links:
Dr. John Cush RheumNow ( View Tweet)
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal.
#LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Aurelie Najm AurelieRheumo ( View Tweet)
DANBIO + Swedish register SGR linked to national birth registers (matched 1:10): RA-pregnancies: higher preterm birth (OR 1.92, 95CI 1.56-2.35) and small gestational age (OR 1.93, 95CI 1.45-2.57). Association strengthened by high disease activity.
#OP0210 @Rheumnow #EULAR2021 https://t.co/Fjm0uxCPgC
Aurelie Najm AurelieRheumo ( View Tweet)
What is the impact of RA on fertility in men:
#OP0211 and #OP0212 @Rheumnow #EULAR2021
Aurelie Najm AurelieRheumo ( View Tweet)
Retrospective RA cohort study: overall risk of dementia ⬆️ in RA (HR 1.38; 95%CI 1.04-1.83) BUT 10-year cumulative incidence of dementia ⬇️:
12.7% in 1980s
7.2% in 1990s
2000s 6.2% Risk no longer significantly ⬆️ for patients w/ RA onset in 2000s! @RheumNow #EULAR2021 #OP0216 https://t.co/TVRTTJjvno
Aurelie Najm AurelieRheumo ( View Tweet)
Serious infections and BioDMARDs: what is the confounding factor?
BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD
Aurelie Najm AurelieRheumo ( View Tweet)
HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up?
#OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy
Aurelie Najm AurelieRheumo ( View Tweet)
Just a reminder: RA-ILD doesn't just happen in early disease; risk continues on long after diagnosis.
PS don't smoke if you have RA; smokers have an adj HR 1.92
PPS don't smoke if you don't want to get RA
PPPS don't smoke.
@MayoClinic POS0210 #EULAR2021 @RheumNow https://t.co/elhvJrK7B4
David Liew drdavidliew ( View Tweet)
Which RA pts have high HAQ? F/U of 2 ERA cohorts [NOAR 1001 pts, #ESPOIR 767 pts] compared pts with high vs lower HAQ. DAS28 was = in 2 groups! But high HAQ occurred in older, females &⬆️fatigue OP0183 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope ( View Tweet)
Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence of RA-BR of 18.7% (some may have been subclinical). POS0522 Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis #EULAR2021 @Janetbirdope
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope Janetbirdope ( View Tweet)
Lower ILD incidence in PsA than RA in a large Nordic registry
⭐️ No significant ⬆️ in ILD in those using MTX
Abs#OP0222
#EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
Robert B Chao, MD doctorRBC ( View Tweet)
Disappointed to have missed lots of interesting sessions at Day 3 #EULAR2021 but look forward to catching up, starting with the difficult-to-treat #rheumatoidarthritis session! I particularly like this helpful summary on complexities & factors to consider in patients with D2T RA. https://t.co/H8n9Q2QNDW
Mrinalini Dey DrMiniDey ( View Tweet)
